S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
NASDAQ:BMEA

Biomea Fusion (BMEA) Stock Price, News & Analysis

$14.95
-0.41 (-2.67%)
(As of 03/28/2024 ET)
Today's Range
$14.85
$15.71
50-Day Range
$13.92
$19.50
52-Week Range
$8.13
$43.69
Volume
809,843 shs
Average Volume
1.32 million shs
Market Capitalization
$533.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.63

Biomea Fusion MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
252.0% Upside
$52.63 Price Target
Short Interest
Bearish
40.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Biomea Fusion in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.29) to ($3.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.21 out of 5 stars

Medical Sector

802nd out of 939 stocks

Pharmaceutical Preparations Industry

376th out of 444 stocks

BMEA stock logo

About Biomea Fusion Stock (NASDAQ:BMEA)

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

BMEA Stock Price History

BMEA Stock News Headlines

BMEA Apr 2024 5.000 put
BMEA Apr 2024 5.000 call
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For
Wall Street Expects 190% Upside for This Biotech Stock
Buy Rating Affirmed for Biomea Fusion Amid Promising Clinical Trials
Biomea Fusion Inc BMEA
Biomea Fusion's Uphill Battle In Diabetes Care
See More Headlines
Receive BMEA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BMEA
Fax
N/A
Employees
103
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$52.63
High Stock Price Target
$90.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+252.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-81,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.69 per share

Miscellaneous

Free Float
26,326,000
Market Cap
$533.80 million
Optionable
Optionable
Beta
-0.48
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

BMEA Stock Analysis - Frequently Asked Questions

Should I buy or sell Biomea Fusion stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMEA shares.
View BMEA analyst ratings
or view top-rated stocks.

What is Biomea Fusion's stock price target for 2024?

8 analysts have issued twelve-month target prices for Biomea Fusion's stock. Their BMEA share price targets range from $33.00 to $90.00. On average, they expect the company's stock price to reach $52.63 in the next twelve months. This suggests a possible upside of 252.0% from the stock's current price.
View analysts price targets for BMEA
or view top-rated stocks among Wall Street analysts.

How have BMEA shares performed in 2024?

Biomea Fusion's stock was trading at $14.52 at the beginning of the year. Since then, BMEA shares have increased by 3.0% and is now trading at $14.95.
View the best growth stocks for 2024 here
.

Are investors shorting Biomea Fusion?

Biomea Fusion saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 11,200,000 shares, an increase of 6.9% from the February 29th total of 10,480,000 shares. Based on an average daily trading volume, of 976,000 shares, the days-to-cover ratio is presently 11.5 days. Currently, 40.6% of the shares of the company are short sold.
View Biomea Fusion's Short Interest
.

When is Biomea Fusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our BMEA earnings forecast
.

How were Biomea Fusion's earnings last quarter?

Biomea Fusion, Inc. (NASDAQ:BMEA) posted its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.04.

What ETF holds Biomea Fusion's stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 113,300 shares of BMEA stock, representing 1.44% of its portfolio.

When did Biomea Fusion IPO?

Biomea Fusion (BMEA) raised $120 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO.

Who are Biomea Fusion's major shareholders?

Biomea Fusion's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.78%), Vanguard Group Inc. (3.78%), Northern Trust Corp (0.62%), Charles Schwab Investment Management Inc. (0.50%), Price T Rowe Associates Inc. MD (0.49%) and Price T Rowe Associates Inc. MD (0.49%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Bihua Chen, Franco Valle, Global Healthcare Ma Cormorant, Michael JM Hitchcock and Rainer M Erdtmann.
View institutional ownership trends
.

How do I buy shares of Biomea Fusion?

Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BMEA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners